PADCEV (enfortumab vedotin-ejfv) for injection
PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Brand Name: PADCEV (enfortumab vedotin-ejfv) for injection, for intravenous use Initial U.S. Approval: 2019
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
PADCEV (enfortumab vedotin-ejfv) for injection
Enfortumab vedotin-ejfv is a type of targeted therapy called an antibody-drug conjugate. It is made of a monoclonal antibody chemically linked to a cancer-killing drug. The monoclonal antibody binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and kills them. Enfortumab vedotin-ejfv may also stimulate the immune system to kill cancer cells.
Padcev is a cancer medicine for treating adults with urothelial cancer (a cancer of the bladder and urinary tract). Padcev is for patients whose cancer is advanced or has spread and who have already had platinum- based chemotherapy and an immunotherapy. It contains the active substance enfortumab vedotin.
A drug used alone or with pembrolizumab to treat adults with certain types of urothelial cancer (a type of cancer in the bladder or urinary tract) that have spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Padcev contains a monoclonal antibody that binds to a protein called nectin-4, which is found on some cancer cells. It also contains an anticancer drug, which may help kill cancer cells. Padcev may also help the immune system kill cancer cells. It is a type of antibody-drug conjugate. Also called enfortumab vedotin.
Enfortumab vedotin is indicated for the treatment of adults with locally advanced (when cancer has grown too large to be surgically removed) or metastatic (when cancer cells spread to other parts of the body) urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.
Drug (Brand / Generic): PADCEV / enfortumab vedotin-ejfv
Current Indications: urothelial cancer (a type of cancer in the bladder or urinary tract)
Marketed by:: Astellas Pharma US, Inc
Approval Date: 2019
Dosage forms and strengths of PADCEV (enfortumab vedotin-ejfv).
For Injection: 20 mg and 30 mg of enfortumab vedotin-ejfv as a lyophilized powder in a single-dose vial for reconstitution.
Find Reference Updates
What is Padcev and how does it work?
Astellas, cited on Nov 20, 2020
FDA approves new type of therapy to treat advanced urothelial cancer
FDA press release, December 18, 2019
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ PADCEV (enfortumab vedotin-ejfv) for injection ”. Confirmation of the order for PADCEV (enfortumab vedotin-ejfv) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – PADCEV
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
PADCEV Sourcing & Delivery
Alleviare India specializes in sourcing and supplying PADCEV, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of PADCEV in India.
How much does PADCEV cost in the India?
Kindly reach out to us for PADCEV (enfortumab vedotin-ejfv) for injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import PADCEV to India?
To import enfortumab vedotin-ejfv PADCEV, patients or government hospitals can place an order on behalf of the patients.
The following documentation is required for the import process:
- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
- Valid prescription from the doctor.
- Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is PADCEV available in India?
PADCEV enfortumab vedotin-ejfv is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of PADCEV (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for PADCEV availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is enfortumab vedotin-ejfv available in India?
On April 3, 2023, the FDA granted accelerated approval to enfortumab vedotin-ejfv (brand name Padcev) with pembrolizumab (brand name Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand PADCEV (enfortumab vedotin-ejfv) for injection. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to PADCEV (enfortumab vedotin-ejfv) for injection , they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
